PDCD1 and non-small cell lung carcinoma: When exploring a correlation between intratumoral neoantigen load and sensitivity to PD-1 blockade, McGranahan et al. have reported that a high clonal neoantigen burden in tumors of anti-PD-1 antibody-treated NSCLC patients is associated with improved clinical outcome [49].